Lua Labs Report — COMT and Estrogen Metabolism: Fast vs. Slow Methylators

Date: 2026-07-13 Researcher: Lua Labs Classification: Hormonal Nutrigenomics Line: L6 — Hormonal Nutrigenomics Sub-topic: 6.1 — COMT and estrogen metabolism: fast vs. slow methylators, implications for cancer and perimenopause

External Sources

Andrade P, Santamarina AB, de Freitas JA, Marum ABRF, Pessoa AFM (2024). "Personalized nutrition and precision medicine in perimenopausal women: A minireview of genetic polymorphisms COMT, FUT2, and MTHFR". Clinics (Sao Paulo), 80:100549. DOI: 10.1016/j.clinsp.2024.100549. PMID: 39642577.
González-Castro TB, Tovilla-Zárate C, Juárez-Rojop I, Pool García S, Genis A, Nicolini H, López Narváez L (2013). "Distribution of the Val108/158Met polymorphism of the COMT gene in healthy Mexican population". Gene, 526(2):454-458. DOI: 10.1016/j.gene.2013.05.068. PMID: 23774690.
Cavalieri EL, Stack DE, Devanesan PD, et al. (1997). "Molecular origin of cancer: Catechol estrogen-3,4-quinones as endogenous tumor initiators". PNAS, 94(20):10937-10942.
Kapoor E, Faubion SS, Kuhle C, Kling JM, Miller VM, Fokken S, Mara K, Moyer AM (2023). "The effect of genetic variation in estrogen transportation and metabolism on the severity of menopause symptoms: a study from the RIGHT 10K cohort". Maturitas, 176:107797. DOI: 10.1016/j.maturitas.2023.107797. PMID: 37595497.
Qin X, Peng Q, Qin A, Chen Z, Lin L, Deng Y, Xie L, Xu J, Li H, Li T, Li S, Zhao J (2012). "Association of COMT Val158Met polymorphism and breast cancer risk: an updated meta-analysis". Diagnostic Pathology, 7:136. DOI: 10.1186/1746-1596-7-136.
Cao Y, Wang D, Liu B, Yao G, Fu Y, Bi Z (2012). "Catechol-O-methyltransferase (COMT) Val158Met polymorphism and risk of osteoporotic fracture". Molecular Biology Reports, 39(3):2975-2979. DOI: 10.1007/s11033-011-1059-9. PMID: 21691708.
Zhu BT, Liehr JG (1996). "Inhibition of catechol-O-methyltransferase-catalyzed O-methylation of 2- and 4-hydroxyestradiol by quercetin. Possible role in estradiol-induced tumorigenesis". Journal of Biological Chemistry, 271(3):1357-1363. DOI: 10.1074/jbc.271.3.1357. PMID: 8576124.
Nagai M, Conney AH, Zhu BT (2004). "Strong inhibitory effects of common tea catechins and bioflavonoids on the O-methylation of catechol estrogens catalyzed by human liver cytosolic catechol-O-methyltransferase". Drug Metabolism and Disposition, 32(5):497-504. DOI: 10.1124/dmd.32.5.497. PMID: 15100171.
Lorenz M, Paul F, Moobed M, Baumann G, Zimmermann BF, Stangl K, Stangl V (2014). "The activity of catechol-O-methyltransferase (COMT) is not impaired by high doses of epigallocatechin-3-gallate (EGCG) in vivo". European Journal of Pharmacology, 740:645-651. DOI: 10.1016/j.ejphar.2014.06.014. PMID: 24972245.

Background Knowledge (what I know before searching)

Catechol-O-methyltransferase (COMT) is a cytosolic and membrane-bound, Mg²⁺-dependent enzyme that transfers a methyl group from S-adenosylmethionine (SAM) to catechol compounds — molecules with two adjacent hydroxyl groups on an aromatic ring. It has two physiologically relevant substrate families that share the same enzymatic bottleneck: (1) catecholamines — dopamine, norepinephrine, epinephrine — and (2) catechol-estrogens — the hydroxylated metabolites of estradiol (E2) and estrone (E1). It is the same enzyme, the same gene (COMT, chromosome 22q11.21), the same functional polymorphism that governs both systems.

The most studied polymorphism is rs4680 (Val158Met in the membrane-bound isoform; Val108Met in the soluble form): a G→A substitution that changes valine to methionine at codon 158/108. The Met allele produces a thermolabile protein with 3-4 times less enzymatic activity than the Val allele. The possible genotypes are Val/Val (fast metabolizer), Val/Met (intermediate), and Met/Met (slow metabolizer). This is popularly known in the neuroscience literature as the "warrior vs. worrier" gene — Met/Met is associated with higher sustained prefrontal dopamine, better cognitive performance under baseline conditions but greater stress reactivity and anxiety, while Val/Val clears catecholamines faster, with the opposite profile.

What the popular narrative almost never mentions is the backup asymmetry between the two systems. Catecholamines have a robust alternate degradation pathway: monoamine oxidase (MAO-A/B) metabolizes them independently of COMT, so a slow COMT genotype is partially buffered by MAO. Catechol-estrogens have no such backup — methylation by COMT is, together with conjugation by sulfotransferases (SULT1A1/1E1) and glucuronidation (UGT1A1, already characterized in L1.4/L1.5), one of the few available inactivation pathways, and the only one that competes directly with oxidation to reactive quinones. This means the reproductive/oncological consequence of a slow COMT genotype could be less biologically buffered than its neuropsychological consequence, even though the popular literature has historically emphasized the latter.

Estradiol and estrone are hydroxylated through three cytochrome P450 pathways: 2-hydroxylation (CYP1A1/CYP3A4, produces 2-OH-E1/E2, considered the "safe pathway" — its methoxy derivative, 2-methoxyestradiol, is antiproliferative and antiangiogenic), 4-hydroxylation (CYP1B1, produces 4-OH-E1/E2, the most reactive pathway with the highest residual affinity for the estrogen receptor), and 16α-hydroxylation (produces 16α-OH-E1, an estriol precursor with sustained proliferative activity). COMT acts downstream of all three hydroxylation pathways at the 2-OH and 4-OH positions (not at 16α-OH, which follows other conjugation routes). If COMT methylates successfully, the result is relatively inert or even protective methoxyestrogens. If it fails to methylate in time — whether due to the Met/Met genotype, lack of SAM (folate/B12 deficiency, MTHFR C677T, topic of L6.2), or competitive inhibition of the enzyme — catechol-estrogens, especially 4-OH, are oxidized by peroxidases and cytochromes into electrophilic semiquinones and quinones. These quinones react with DNA to form depurinating adducts that generate abasic sites, whose error-prone repair introduces the mutations that the literature describes as initiators of breast, endometrial, and other hormone-dependent tissue cancers (Cavalieri/Rogan model).

This is exactly the "who" that L5.6 left open: L5 established that hormonal epigenetic marks (estrogen receptor sensitivity, peripheral adipose aromatization, ovarian epigenetic clock) are partially reversible with diet/exercise/sleep, but with extreme heterogeneity of response between women (Fitzgerald 2023: -1.22 to -11.01 Horvath years with the same intervention). COMT is one of the most direct candidate genetic modules for explaining that heterogeneity, because in addition to metabolizing estrogens, it consumes the same SAM pool that feeds the DNA methylation machinery L5 wants to modulate.

Findings from Recent Papers

Andrade et al. 2024 (Clinics) is the first review dedicated specifically to COMT in the context of perimenopause (not just cancer). It confirms the standard mechanism — 25-40% activity reduction in Met carriers, prolonged half-life of catecholamines and catechol-estrogens — and proposes, without robust clinical trial evidence, that the interaction between rs4680 and perimenopausal hormonal fluctuation "may affect energy metabolism and thermoregulation, contributing to vasomotor symptoms." This is a mechanistically plausible hypothesis but not yet validated by large cohorts — as confirmed by the next finding.

Kapoor et al. 2023 (Maturitas, RIGHT 10K cohort, Mayo Clinic) is the most important scientific correction of this session. In 60 peri/postmenopausal women, higher COMT activity was associated with a lower MRS (Menopause Rating Scale) score in the somatic domain (difference of 1.48 points, p=0.06) — but the association did not survive adjustment for hormone therapy use (adjusted difference 1.22, p=0.12), and the authors explicitly conclude that "the current study showed no association between genetic variation in estrogen metabolism/transport and menopause symptom severity." With n=60 the study is clearly underpowered (80% of the sample had high activity, leaving ~12 women in the low-activity group) — it does not refute the mechanism, but it demands calibrated expectations: COMT alone, without covariates, does not robustly predict symptom severity in small samples.

Qin et al. 2012 (Diagnostic Pathology), the largest available meta-analysis on COMT and breast cancer (56 studies, 34,358 cases, 45,429 controls), found no significant population-level association between Val158Met and breast cancer risk under any genetic model. This is consistent with the general pattern of "low-penetrance" genes: the effect of COMT alone is small and depends on gene-environment interaction (total estrogenic load, exposure duration, methylation cofactors) more than on an isolated main effect — the same pattern L2, L3, and L5 have repeatedly found with individual polymorphisms.

González-Castro et al. 2013 (Gene) provides the most actionable data point from this session: in 431 healthy Mexican volunteers, the frequency of the Met allele (slow metabolizer) was 63% overall — 57% in Tabasco, up to 85% in Mexico City — compared to 54% in Caucasian populations, 29% in Asian, and 34% in African reference populations. The Mexican population studied has a meaningfully higher slow-allele frequency than the Caucasian population on which most of the clinical COMT-estrogen-cancer literature cited above has been built.

Zhu & Liehr 1996 and Nagai/Conney/Zhu 2004 document, in animal and in vitro models respectively, that quercetin and green tea catechins (especially EGCG, IC₅₀ of 0.04-0.07 µM for 2-OH-E2, the most potent inhibition reported) are direct inhibitors of COMT via a mixed competitive/non-competitive mechanism — in hamsters, quercetin increased renal 2-OH-E2/4-OH-E2 by 80%/59% and reduced their methylated excretion by 63-65%. However, Lorenz et al. 2014, the only available in vivo human trial (n=24, single 750 mg EGCG dose), found that erythrocyte COMT activity was not reduced — in fact it increased ~24% at 2 hours. This in vitro/animal vs. human in vivo discordance is the basis of Hypothesis 65 of this session.

Complete Molecular/Endocrine Mechanism

Cholesterol → Estradiol (E2) / Estrone (E1)  [ovary, adipose — inherited from L5.3]
                    │
     ┌──────────────┼───────────────────┐
     ▼                                  ▼                        ▼
CYP1A1 / CYP3A4                     CYP1B1                CYP3A4 / CYP1A1
(2-hydroxylation)                (4-hydroxylation)        (16α-hydroxylation)
     │                                  │                        │
  2-OH-E1/E2                       4-OH-E1/E2                16α-OH-E1
"safe pathway"                "reactive pathway" —            (→ estriol,
2-MeOE2 final:                  higher residual ERα             proliferative,
antiproliferative,              affinity                        distinct
antiangiogenic                  >99% of depurinating             pathway,
     │                           DNA adducts originate            outside COMT)
     │                           here (Cavalieri 1997)
     └──────────────┬───────────────────┘
                     ▼
        COMT (rs4680 Val158Met) + SAM (folate/B12/MTHFR cycle — bridge to L6.2)
        + Mg²⁺ (cofactor)
                     │
       ┌─────────────┴──────────────┐
       ▼ successful methylation      ▼ insufficient methylation
  2-/4-methoxyestrogens         (Met/Met, low SAM, or COMT
  relatively inert/               competitively inhibited
  protective                      — high-dose quercetin/EGCG)
                                       │
                                       ▼
                            Oxidation to semiquinones → quinones
                            catechol-estrogen-3,4 (via peroxidases/CYP)
                                       │
                            ┌──────────┴───────────┐
                            ▼                       ▼
                  Depurinating DNA adducts       Redox cycle
                  4-OHE1(E2)-1-N3Ade/N7Gua        semiquinone-quinone
                  → abasic sites                 → ROS (O2•⁻, H2O2)
                  → error-prone repair            → tissue oxidative
                     → mutation                       stress
                            │                       │
                            └──────────┬────────────┘
                                       ▼
                    Initiation of hormone-dependent cancer
                    (breast, endometrium) — risk modulated by
                    TOTAL accumulated exposure, not isolated genotype

Parallel pathway — SAME enzyme, SAME bottleneck:
Catecholamines (dopamine, norepinephrine) → COMT → inert metabolite
                                              ↕ (share SAM + genotype)
                             MAO-A/B (backup — NO equivalent in estrogenic pathway)

Cross-Synthesis with Previous Findings

Direct bridge to L2 (HPA-HPO): L2.1 and L2.3 had already identified COMT Met/Met as an individual-variability polymorphism, with the reading "sustained catecholamines → prolonged CRH-PVN." L6.1 reveals this is not a coincidence of shared vocabulary: it is the same enzyme, the same allele, acting on two distinct catechol substrates through the same bottleneck. A Met/Met woman not only has greater HPA reactivity (L2) — she simultaneously, and for the same molecular reason, has a reduced capacity to neutralize genotoxic catechol-estrogens (L6.1). This is the basis of Hypothesis 63.
Bridge to L5.2 and L5.3: L5.2 assesses how much signal a given amount of estradiol generates (receptor sensitivity); L5.3 assesses how much estrogen adipose tissue produces (peripheral aromatization). COMT measures a distinct, downstream dimension: how toxic the metabolite becomes once the signal has already occurred. A woman can have normal receptor sensitivity and adipose aromatization and still accumulate more oxidative/genotoxic burden if her COMT is slow — these are orthogonal, not redundant, axes.
Direct and critical bridge to L5.6 (Reversibility): the "Epigenetic Reversal Stack" from L5.6 recommended quercetin and green tea polyphenols as HDAC inhibitors/TET support to reverse ESR1 methylation. The literature in this session shows those same compounds are, in the same concentration range studied in vitro, direct inhibitors of COMT. This is the first time in the lab that a formulation from one line (L5) enters potential mechanical tension with a finding from another (L6) — see Hypothesis 65.
Bridge to L1.4/L1.5: UGT1A1/UGT2B15 (glucuronidation) and SULT1A1/1E1 (sulfation) were already mentioned as parallel conjugation pathways for catechol-estrogens and phytoestrogens. COMT is the third phase-II pathway, and the only one of the three specifically dedicated to neutralizing the catechol group before it oxidizes — the other two act on different functional groups and do not directly compete for the same reactive substrate.
Forward bridge (L6.2, L6.3, L6.6): COMT depends on SAM, whose availability governs L6.2 (MTHFR/folate) — more folate/B12/betaine does not compete with L5.6's epigenetic reversal (which operates through TET-mediated demethylation, not SAM restriction); in fact, the same methyl donors (leafy greens, liver, egg, beet) recommended in the "Epigenetic Reversal Stack" directly support COMT function. COMT acts downstream of CYP1A1/CYP1B1 (L6.3, next sub-topic): the worst combinatorial scenario is high-activity CYP1B1 (more 4-OH-E2 produced) + slow COMT (less 4-OH-E2 cleared) — a compound genotype L6.3 must quantify. GSTP1 (L6.6) acts on quinones already formed via glutathione conjugation — the final rescue mechanism if COMT fails.

Lua Labs Hypotheses

Hypothesis 63: Double Catechol Burden — COMT Met/Met as an HPA-Estrogenic Convergence Node

Statement: in perimenopausal women, the COMT Met/Met genotype produces simultaneous and correlated vulnerability in two systems Lua Labs had until now characterized as independent — HPA axis reactivity (L2.1-L2.3, sustained catecholamines) and estrogenic genotoxic burden (L6.1, unmethylated catechol-estrogens) — because both share the same enzymatic bottleneck. The combined severity of anxiety/stress-reactivity symptoms AND vasomotor/oxidative-burden symptoms should co-occur more frequently than expected by chance in this subpopulation.

Proposed mechanism: COMT methylates both catecholamines and catechol-estrogens with the same machinery (SAM + Mg²⁺). Met/Met reduces enzymatic activity 3-4x for both substrates simultaneously. Unlike catecholamines (with MAO-A/B backup), catechol-estrogens have no equivalent backup pathway — the estrogenic consequence of the slow genotype could be proportionally greater than the neuropsychological one, even though the latter is the most studied and communicated.

Confidence level: Medium. The enzymatic mechanism (same enzyme, same general substrate class, dual function) is established biochemistry and requires no further validation. The prediction of specific symptomatic co-occurrence in this subpopulation is new and untested.

How to validate:

With a formal study: cohort with voluntary rs4680 genotyping (n≥150), comparing somatic MRS + PSS-4 + Greene Score between Val/Val, Val/Met, Met/Met, controlling for hormonal stage and HRT use (a direct lesson from Kapoor 2023's limitation).

Limitations: the weakest link is that Kapoor 2023 (the only recent cohort study to test COMT and menopause symptom severity) found no robust association after adjusting for HRT, with a small n. H63 predicts an interaction (HPA × estrogenic) rather than a main effect of COMT alone — that type of interaction requires larger samples than are currently available in the literature.

Hypothesis 64: LATAM Underestimation of the Slow-Metabolizer Phenotype

Statement: the COMT-estrogen-cancer clinical literature, built mostly on Caucasian and Asian populations, systematically underestimates the prevalence of the "slow metabolizer" phenotype (Met/Met, and Met carriers in general) in the Mexican/LATAM population — with a documented Met allele frequency of 63% (up to 85% in the Mexico City sample) versus 54% in Caucasians.

Proposed mechanism: no new biological mechanism — this is a population genetics finding with direct consequences for risk communication. If the proportion of women with reduced COMT activity is meaningfully higher in the LATAM population than in the reference population of available clinical studies, then the "no significant population-level association" conclusions (Qin 2012, mostly non-LATAM cohorts) may not generalize directly, and risk/symptom management messages calibrated on Western literature could underestimate the relevance of this pathway for Latin American women.

Confidence level: Medium-high for the population-level data point (single but methodologically solid source, n=431, with explicit contrast against three reference populations); low for the derived clinical implication (no clinical outcome study — cancer or symptom severity — exists specifically in the Mexican/LATAM population stratified by COMT).

How to validate:

With a formal study: replicate the González-Castro design in an expanded, geographically diverse LATAM sample (Mexico, Colombia, Argentina), cross-referencing results with self-reported symptom severity from participants.

Limitations: a single allele-frequency study, in only two regions of Mexico (Tabasco and Mexico City) — it does not represent the full genetic diversity of LATAM (variable indigenous/European/African admixture by country and region). Extrapolating to "all of LATAM" is a generalization that must be corrected as more regional data become available.

Hypothesis 65: The Reversal Stack Paradox — COMT-Inhibiting Polyphenols in Slow Methylators

Statement: the polyphenols recommended in L5.6's "Epigenetic Reversal Stack" (quercetin, green tea catechins/EGCG) as epigenetic reversibility support (HDAC inhibition, TET activation) are, in the same dose range studied in vitro and in animal models, direct and potent inhibitors of COMT — creating potential mechanical tension specifically in the subgroup of COMT Met/Met women, whose capacity to clear catechol-estrogens is already reduced by genotype before any additional supplementation-driven inhibition.

Proposed mechanism: quercetin (Zhu & Liehr 1996) and EGCG (Nagai 2004) inhibit the O-methylation of 2-OH-E2/4-OH-E2 by COMT through a mixed competitive/non-competitive mechanism, with low micromolar IC₅₀ (EGCG: 0.04-0.5 µM, the most potent inhibition reported for any dietary polyphenol studied). In an animal model, quercetin increased tissue catechol-estrogen accumulation by 59-80% and reduced their methylated excretion by 63-65%. However, the only available in vivo human data point (Lorenz 2014, n=24, single 750 mg EGCG dose) found no impairment of erythrocyte COMT activity — in fact, a 24% increase. This discordance between the animal/in vitro model and the single human data point is central to calibrating the confidence level of this hypothesis: erythrocytes may not represent hepatic/mammary COMT activity relevant to estrogen metabolism, and a single dose does not represent the chronic high-dose supplementation recommended in popular "estrogen detox" protocols.

Confidence level: Low-medium. The enzymatic inhibition mechanism is well documented in vitro; clinical relevance in humans, with chronic supplementation and in target tissue (not erythrocyte), remains unresolved, and the only available data point runs counter to the concern.

How to validate:

With a formal study: crossover trial in COMT-genotyped women (Met/Met vs. Val/Val), chronic supplementation (4-8 weeks) with commercially used doses of quercetin/EGCG, measuring urinary catechol-estrogen metabolites (2-OH/4-OH/2-MeOE2 ratio) — not just blood enzymatic activity.

Limitations: this is the weakest-link hypothesis of the session — it depends on extrapolating from an animal model (hamster, 1996) and an in vitro assay (2004) to a human chronic-supplementation context that the only available in vivo study (acute, single dose, blood) does not confirm. It should not be communicated as an established risk; it should be treated as an open question shared by L5.6 and L6.1 that deserves resolution before indiscriminately recommending high doses of these polyphenols.

Sub-hypothesis 65a — Genotype-Dependent Sequencing: extending the logic of TES (H62, L5.6 — intervention sequence matters, not just content), in COMT Met/Met women the optimal sequence should place (1) upstream support — cruciferous vegetables/indole-3-carbinol to favor 2-hydroxylation over 4-hydroxylation (reducing the substrate that needs clearing) and (2) cofactor support (folate/B12/magnesium, already present in the Reversal Stack) — before (3) introducing high-dose COMT-inhibiting polyphenols. Doing it in the reverse order would simultaneously maximize 4-OH-E2 production (if upstream is not adjusted first) and inhibit its clearance pathway — the worst combined scenario. Confidence level low; this is a logical extrapolation of independent mechanisms, not a tested prediction.

Candidate Formulation: Catechol Clearance Foundation (CCF)

Compounds (dietary/behavioral, no pharmacological supplementation):

Slow Arm (Met/Met or high-reactivity-plus-vasomotor-burden phenotype proxy): raw/lightly steamed cruciferous vegetables 4-5×/week (broccoli, Brussels sprouts, radish — favor CYP1A1 over CYP1B1, reducing 4-OH substrate); methyl donors from L5.6's Reversal Stack (leafy greens, egg, liver, beet) to sustain SAM; magnesium (direct COMT cofactor); explicit moderation of concentrated high-dose quercetin/EGCG supplements (whole-food polyphenols in habitual amounts, no mega-doses) until H65 is resolved; alcohol moderation (a known independent modifier of estrogenic burden).
Fast Arm (Val/Val): no specific polyphenol restrictions; L5.6's Reversal Stack applies unmodified.
Intermediate Arm (Val/Met, population majority): a moderate version of the Slow Arm, without strict polyphenol restriction but with attention to doses in concentrated supplements.

Target population: Carmen (47, perimenopause, primary priority); also relevant for Sofía (28) with a family history of breast/endometrial cancer, given that genotoxic burden is cumulative across reproductive life, not exclusive to the perimenopausal transition.

Complementary mechanisms: upstream (reduces 4-OH-E2 production via CYP1A1/CYP1B1), cofactor (sustains SAM/Mg²⁺ for COMT), and precautionary (avoids additional inhibition of the clearance pathway in those already genotype-compromised) — three non-redundant intervention points on the same pathway.

Regulatory status: 100% dietary/behavioral, GRAS. No component requires prescription.

Requires validation: arm stratification depends on knowing or inferring COMT genotype/phenotype — without that, this is a research formulation, not a personalizable recommendation today.

Individual Variability

rs4680 (Val158Met) and the full COMT haplotype: COMT's real functional effect depends on a haplotype block of at least 4 common SNPs (including rs4633, rs4818, rs6269), not just isolated rs4680 — the pain literature (Nackley et al.) has shown that specific combinations of these SNPs (the "LPS," "APS," "HPS" haplotypes) predict enzymatic activity better than rs4680 alone.
MTHFR C677T/A1298C (next sub-topic, L6.2): determines SAM availability; TT/TT carriers with low folate would face a "double hit" with COMT Met/Met — less enzyme AND less methyl-donor substrate for the enzyme they do have.
CYP1B1*3 (Leu432Val, next sub-topic L6.3): determines how much 4-OH-E2 is produced upstream. The combination of high-activity CYP1B1 + COMT Met/Met is, in theory, the compound genotype of greatest relative risk (more substrate produced, less cleared) — to be quantified in L6.3.
GSTP1 (L6.6): final rescue pathway — conjugates already-formed quinones with glutathione, acting after COMT has already failed to prevent their formation.
MAOA: partial backup for catecholamines (not for catechol-estrogens) — modulates how much of the Met/Met phenotype is expressed as an HPA symptom versus exclusively as estrogenic burden.
Ancestry/geography: documented Met allele frequency of 63% in the general Mexican population (57-85% depending on region) versus 54% Caucasian, 29% Asian, 34% African — population variability with direct consequences for calibrating risk messaging.
Cumulative exposure (inherited from L5.4): the COMT genotype does not act in a vacuum — the total catechol-estrogen burden that needs clearing depends on early xenoestrogen exposure, total ovulatory cycles, contraceptive/HRT use, and visceral adiposity. A slow genotype with low cumulative exposure may carry less absolute risk than a fast genotype with high cumulative exposure.